Global GLP-1 Receptor Agonist Industry will surpass the US$ 11.24 Billion by 2032, driven by the rising diabetes epidemic | FMI

The global GLP-1 Receptor Agonist Industry has been experiencing remarkable growth in recent years, and this trend shows no signs of slowing down. GLP-1 receptor agonists are a class of medications primarily used to treat type 2 diabetes mellitus, but their therapeutic potential extends beyond diabetes management. These drugs mimic the action of glucagon-like peptide-1 …